Skip to content
BioWa, Inc. logo — PROVEN TECHNOLOGY. PROVEN TEAM. PROVEN COLLABORATORS.

BioWa, Inc.

PROVEN TECHNOLOGY. PROVEN TEAM. PROVEN COLLABORATORS.

Founded 2003 United States Princeton, United States 9 employees Biotechnology, Health Care

General Information

Company Name BioWa, Inc.
Founded Year 2003
Location United States Princeton, United States
Employees 9
Industries Biotechnology, Health Care
Social

BounceWatch is an independent company data service, not affiliated with BioWa, Inc.. To contact BioWa, Inc., visit biowa.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BioWa, Inc. compare?

A PDF of BioWa, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BioWa, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BioWa, Inc.

BioWa, Inc. is a U.S. subsidiary of Kyowa Kirin and the exclusive worldwide licensor of Potelligent® Technology, a proprietary technology that creates 100% fucose-free monoclonal antibodies that demonstrate a marked increase in antibody-dependent cellular cytotoxicity (ADCC). This technology is a critical breakthrough in the biotechnology and healthcare industries as it enhances the ability of antibodies to kill tumor cells. Founded in 2003, BioWa has proven its prowess in the field, with Mab potency shown to increase up to 100 fold both in vitro and in vivo. With a proven technology, proven team, and proven collaborators, the company stands as a promising player in the biotechnology sector, offering lucrative opportunities for potential investors.

Business keywords: Monoclonal Antibodies, ADCC Enhancement, Cancer Treatment, Immunotherapy, Medical Technology, BioPharma, Fucose-Free Antibodies, Potelligent® Technology, Kyowa Kirin, BioWa, Innovation, Drug Development, Research and Development, Collaborations

No funding data available for BioWa, Inc. yet.

BioWa, Inc. Alternatives & Competitors

View All Alternatives
BioWa, Inc. vs

Advancing the future of immuno-oncology with innovative monoclonal antibody treatments

Series B
7 employees
Biotechnology, Health Care
BioWa, Inc. vs

Wuhan YZY Biopharma Co. Ltd. YZY Biopharma is a biotech company whose vision is to develop new cl...

Series C
55 employees
Biotechnology, Health Care
BioWa, Inc. vs

We create improved treatment options for cancer patients through unique immunotherapy opportunities

Venture round
6 employees
Biotechnology, Health Care

FAQ About BioWa, Inc.

PROVEN TECHNOLOGY. PROVEN TEAM. PROVEN COLLABORATORS.
BioWa, Inc. was founded in 2003.
BioWa, Inc. is headquartered in Princeton, United States.
BioWa, Inc. operates in Biotechnology and Health Care. Its work centres on Monoclonal Antibodies, ADCC Enhancement, Cancer Treatment and Immunotherapy.
BioWa, Inc. has approximately 9 employees.
Top alternatives and competitors to BioWa, Inc. include GamaMabs Pharma, Wuhan YZY Biopharma Co. Ltd., Caedo Oncology AS, Apollomics, Telormedix. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BioWa, Inc. and GamaMabs Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BioWa, Inc., https://bouncewatch.com/company/biowa-inc, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout